{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:34:16Z","timestamp":1770482056091,"version":"3.49.0"},"reference-count":178,"publisher":"Elsevier BV","issue":"6","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.autrev.2013.12.001","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T12:47:03Z","timestamp":1389358023000},"page":"655-667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Raynaud's phenomenon: From molecular pathogenesis to therapy"],"prefix":"10.1016","volume":"13","author":[{"given":"Marcella","family":"Prete","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Celeste","family":"Fatone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Favoino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.12.001_bb0005","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s004200050021","article-title":"Pathophysiology and classification of the vibration white finger","volume":"73","author":"Noel","year":"2000","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.autrev.2013.12.001_bb0010","first-page":"580","article-title":"Vascular toxicity associated with antineoplastic agents","volume":"19","author":"Doll","year":"1992","journal-title":"Semin Oncol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.autrev.2008.07.002","article-title":"Treatment of Raynaud's phenomenon","volume":"8","author":"Garcia-Carrasco","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice. Raynaud's Phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.12.001_bb0030","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2165\/00003495-200767040-00003","article-title":"The diagnosis and treatment of Raynaud's phenomenon: a practical approach","volume":"67","author":"Pope","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2013.12.001_bb0035","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.23555","article-title":"Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination)","volume":"58","author":"Ingegnoli","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0040","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/art.20988","article-title":"The incidence and natural history of Raynaud's phenomenon in the community","volume":"52","author":"Suter","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s10067-005-0077-1","article-title":"Raynaud's phenomenon: prevalence in an Italian population sample","volume":"25","author":"De Angelis","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0050","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1529-0131(199902)42:2<306::AID-ANR13>3.0.CO;2-G","article-title":"Different factors influencing the expression of Raynaud's phenomenon in men and women","volume":"42","author":"Fraenkel","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0055","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rdc.2004.10.005","article-title":"Estrogens and neuropeptides in Raynaud's phenomenon","volume":"31","author":"Generini","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2013.12.001_bb0065","doi-asserted-by":"crossref","first-page":"A377","DOI":"10.1016\/j.autrev.2011.11.001","article-title":"The role of gender and organ specific autoimmunity","volume":"11","author":"Nussinovitch","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjmed.2006.06.007","article-title":"Smoking, alcohol consumption, and Raynaud's phenomenon in middle age","volume":"120","author":"Suter","year":"2007","journal-title":"Am J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2013.12.001_bb0075","first-page":"iii19","article-title":"Digital ulcers: overt vascular disease in systemic sclerosis","volume":"48","author":"Steen","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0398-0499(06)76512-X","article-title":"Heredity and genetic aspects of Raynaud's disease","volume":"31","author":"Pistorius","year":"2006","journal-title":"J Mal Vasc"},{"key":"10.1016\/j.autrev.2013.12.001_bb0085","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/ajmg.a.33659","article-title":"Novel COL4A1 mutations associated with HANAC syndrome: a role for the triple helical CB3[IV] domain","volume":"152A","author":"Plaisier","year":"2010","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.autrev.2013.12.001_bb0090","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 3","key":"10.1016\/j.autrev.2013.12.001_bb0095","first-page":"iii33","article-title":"Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis","volume":"45","author":"Sunderkotter","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0100","series-title":"Vascular surgery: principle and practise","first-page":"903","article-title":"Raynaud's syndrome and upper extremities small artery occlusive diseases","author":"Edwards","year":"2004"},{"key":"10.1016\/j.autrev.2013.12.001_bb0105","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1056\/NEJMicm1104140","article-title":"Images in clinical medicine. Lingual Raynaud's phenomenon","volume":"366","author":"Katada","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.12.001_bb0110","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3899\/jrheum.091117","article-title":"Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease","volume":"37","author":"Chikura","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0115","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1024\/0301-1526\/a000003","article-title":"Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia","volume":"39","author":"Heidrich","year":"2010","journal-title":"Vasa"},{"key":"10.1016\/j.autrev.2013.12.001_bb0120","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/000331979404500802","article-title":"Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients","volume":"45","author":"Planchon","year":"1994","journal-title":"Angiology"},{"key":"10.1016\/j.autrev.2013.12.001_bb0125","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/art.1780390717","article-title":"Familial aggregation of primary Raynaud's disease","volume":"39","author":"Freedman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0130","first-page":"485","article-title":"Raynaud's phenomenon: a proposal for classification","volume":"10","author":"LeRoy","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0889-857X(21)01038-3","article-title":"Early detection of connective tissue disease in patients with Raynaud's phenomenon","volume":"16","author":"Kallenberg","year":"1990","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2013.12.001_bb0140","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","article-title":"Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions","volume":"49","author":"Amanzi","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.autrev.2005.08.004","article-title":"Digital ulcers in patients with systemic sclerosis","volume":"5","author":"Chung","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0150","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.autrev.2006.12.006","article-title":"Vascular complications of scleroderma","volume":"6","author":"Guiducci","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0155","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0160","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.rdc.2005.04.006","article-title":"Raynaud's phenomenon in mixed connective tissue disease","volume":"31","author":"Grader-Beck","year":"2005","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2013.12.001_bb0165","first-page":"429","article-title":"Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population","volume":"35","author":"Maldonado","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0170","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0961203310366572","article-title":"Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus","volume":"19","author":"Nossent","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.12.001_bb0175","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10067-009-1175-2","article-title":"Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients","volume":"28","author":"Vaz","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0180","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.3899\/jrheum.071025","article-title":"The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis","volume":"35","author":"Pope","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0185","first-page":"726","article-title":"Raynaud's phenomenon in primary Sjogren's syndrome. Prevalence and clinical characteristics in a series of 320 patients","volume":"29","author":"Garcia-Carrasco","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0190","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1007\/s00296-011-2109-2","article-title":"Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon","volume":"32","author":"Pavlov-Dolijanovic","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0195","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0200","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/kep447","article-title":"Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy","volume":"49","author":"Ingegnoli","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0205","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2133.2007.07819.x","article-title":"Assessment of nailfold capillaroscopy by \u00d730 digital epiluminescence (dermoscopy) in patients with Raynaud phenomenon","volume":"156","author":"Beltran","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0210","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1365-2133.2008.09004.x","article-title":"Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors","volume":"160","author":"Sunderkotter","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0215","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2013.12.001_bb0220","doi-asserted-by":"crossref","first-page":"854941","DOI":"10.1155\/2012\/854941","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction","volume":"2012","author":"Dhala","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0225","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10067-010-1432-4","article-title":"Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon","volume":"30","author":"Shinjo","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0230","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0961203310367656","article-title":"Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus","volume":"19","author":"Gronhagen","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.12.001_bb0235","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MD.0b013e3181cb449c","article-title":"Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China","volume":"89","author":"Tang","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0240","first-page":"349","article-title":"Raynaud's phenomenon in systemic lupus erythematosus","volume":"62","author":"Lavras Costallat","year":"1995","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.autrev.2013.12.001_bb0245","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-012-2449-6","article-title":"Is there a difference in systemic lupus erythematosus with and without Raynaud's phenomenon?","volume":"33","author":"Pavlov-Dolijanovic","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00296-010-1565-4","article-title":"Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case\u2013control study from a single center","volume":"32","author":"Padovan","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0255","first-page":"118","article-title":"A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies","volume":"31","author":"Cavazzana","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0260","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1191\/0961203302lu144oa","article-title":"Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients","volume":"11","author":"Furtado","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.12.001_bb0265","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00296-009-1255-2","article-title":"Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome","volume":"31","author":"Cefle","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0270","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10067-007-0721-z","article-title":"Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies","volume":"27","author":"Choojitarom","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0275","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/0961203310365883","article-title":"Clinical analysis of systemic lupus erythematosus with gastrointestinal manifestations","volume":"19","author":"Xu","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.12.001_bb0280","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00296-010-1597-9","article-title":"Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus","volume":"32","author":"Sayarlioglu","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0285","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1177\/0961203309106643","article-title":"Prevalence, risk factors and outcome of digital gangrene in 2684 lupus patients","volume":"18","author":"Liu","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2013.12.001_bb0290","article-title":"Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature","author":"Prete","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0295","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1046\/j.1365-2133.1998.02458.x","article-title":"The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease","volume":"139","author":"Ohtsuka","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10067-004-0988-2","article-title":"Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD)","volume":"24","author":"De Angelis","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0305","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00296-011-2234-y","article-title":"Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year","volume":"33","author":"Guerrero","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0310","first-page":"305","article-title":"Extra-articular manifestations of rheumatoid arthritis: results of a university hospital of 526 patients in Turkey","volume":"24","author":"Calguneri","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0315","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/rheumatology\/35.8.752","article-title":"Raynaud's phenomenon in rheumatoid arthritis","volume":"35","author":"Saraux","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0320","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","article-title":"Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0325","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.semarthrit.2008.04.002","article-title":"Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon","volume":"39","author":"Willeke","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0330","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MD.0b013e3181579781","article-title":"Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature","volume":"86","author":"Launay","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0335","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-008-0717-2","article-title":"A case of MCTD overlapped by Takayasu's arteritis, presenting Raynaud's phenomenon as the initial manifestation of both diseases","volume":"29","author":"Lim","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0340","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0895-7967(03)00023-1","article-title":"Buerger's disease in the 21st century: diagnosis, clinical features, and therapy","volume":"16","author":"Mills","year":"2003","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.autrev.2013.12.001_bb0345","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-011-1727-0","article-title":"The association of Raynaud's syndrome with rheumatoid arthritis\u2014a meta-analysis","volume":"30","author":"Hartmann","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0350","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0008-6363(96)00183-6","article-title":"Raynaud's phenomenon","volume":"33","author":"Belch","year":"1997","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2013.12.001_bb0355","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/occmed\/kqg097","article-title":"Thoracic outlet syndrome\u2014aspects of diagnosis in the differential diagnosis of hand-arm vibration syndrome","volume":"53","author":"Cooke","year":"2003","journal-title":"Occup Med (Lond)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0360","first-page":"283","article-title":"Calciphylaxis in a patient with POEMS syndrome without renal failure and\/or hyperparathyroidism. A case report","volume":"19","author":"De Roma","year":"2004","journal-title":"Ann Ital Med Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0365","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.autrev.2008.02.001","article-title":"Rheumatic disorders as paraneoplastic syndromes","volume":"7","author":"Racanelli","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0370","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-011-2122-5","article-title":"The association of Raynaud's syndrome with carpal tunnel syndrome: a meta-analysis","volume":"32","author":"Hartmann","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2013.12.001_bb0375","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1368-5031.2005.00566a.x","article-title":"Cyclosporine\u2014a treatment and a rare complication: Raynaud's phenomenon","volume":"59","author":"Arinsoy","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.autrev.2013.12.001_bb0380","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/0003319711432861","article-title":"The association of Raynaud syndrome with beta-blockers: a meta-analysis","volume":"63","author":"Mohokum","year":"2012","journal-title":"Angiology"},{"key":"10.1016\/j.autrev.2013.12.001_bb0385","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2012.43.2872","article-title":"Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion","volume":"31","author":"McGrath","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0390","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud's phenomenon","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.12.001_bb0395","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/304129a0","article-title":"Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing","volume":"304","author":"Rosenfeld","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.12.001_bb0400","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jocn.2009.03.042","article-title":"Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury","volume":"17","author":"Chen","year":"2010","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.autrev.2013.12.001_bb0405","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/313054a0","article-title":"Calcitonin gene-related peptide is a potent vasodilator","volume":"313","author":"Brain","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.12.001_bb0410","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.drudis.2008.12.009","article-title":"Modulating receptor function through RAMPs: can they represent drug targets in themselves?","volume":"14","author":"Sexton","year":"2009","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.autrev.2013.12.001_bb0415","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.1996.tb16221.x","article-title":"Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon","volume":"134","author":"Bunker","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0420","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/014107689408700703","article-title":"Cutaneous nerve fibre depletion in vibration white finger","volume":"87","author":"Goldsmith","year":"1994","journal-title":"J R Soc Med"},{"key":"10.1016\/j.autrev.2013.12.001_bb0425","first-page":"561","article-title":"Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis","volume":"8","author":"Matucci-Cerinic","year":"1990","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0430","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3940(01)02097-3","article-title":"Colocalization of neuronal nitric oxide synthase and neurokinin-1 receptor in striatal interneurons in the rat","volume":"310","author":"Li","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.autrev.2013.12.001_bb0435","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2174\/0929867043364748","article-title":"Tachykinins and tachykinin receptors: structure and activity relationships","volume":"11","author":"Almeida","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.autrev.2013.12.001_bb0440","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3940(98)00926-4","article-title":"Smooth muscle cells are the site of neurokinin-1 receptor localization in the arterial supply of the rat sciatic nerve","volume":"259","author":"Kummer","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.autrev.2013.12.001_bb0445","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.it.2009.03.006","article-title":"Neurokinin 1 receptor isoforms and the control of innate immunity","volume":"30","author":"Tuluc","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0450","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0143-4179(97)90001-9","article-title":"The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation","volume":"31","author":"Quartara","year":"1997","journal-title":"Neuropeptides"},{"key":"10.1016\/j.autrev.2013.12.001_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0143-4179(98)90015-4","article-title":"The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles","volume":"32","author":"Quartara","year":"1998","journal-title":"Neuropeptides"},{"key":"10.1016\/j.autrev.2013.12.001_bb0460","first-page":"119","article-title":"Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma","volume":"28","author":"Freedman","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0465","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1046\/j.1365-2125.1999.00958.x","article-title":"Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease","volume":"47","author":"Smith","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0470","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1476-5381.2011.01676.x","article-title":"VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins","volume":"166","author":"Couvineau","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0475","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.peptides.2007.04.026","article-title":"Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology","volume":"28","author":"Laburthe","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.autrev.2013.12.001_bb0480","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1074\/jbc.C200629200","article-title":"Novel receptor partners and function of receptor activity-modifying proteins","volume":"278","author":"Christopoulos","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2013.12.001_bb0485","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/path.1711640310","article-title":"Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis","volume":"164","author":"Terenghi","year":"1991","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0490","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/S0196-9781(02)00265-6","article-title":"Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice","volume":"23","author":"Bangale","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.autrev.2013.12.001_bb0495","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.autrev.2010.02.012","article-title":"Phosphodiesterase inhibitors in the management of autoimmune disease","volume":"9","author":"Shenoy","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0500","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/1529-0131(200008)43:8<1886::AID-ANR27>3.0.CO;2-S","article-title":"Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma","volume":"43","author":"Flavahan","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0505","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/01.RES.0000128407.45014.58","article-title":"Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation","volume":"94","author":"Bailey","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.autrev.2013.12.001_bb0510","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/ard.60.5.487","article-title":"Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)","volume":"60","author":"Matucci-Cerinic","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0515","doi-asserted-by":"crossref","first-page":"e13918","DOI":"10.1371\/journal.pone.0013918","article-title":"Serum neurotrophin profile in systemic sclerosis","volume":"5","author":"Lise","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2013.12.001_bb0520","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1024\/0301-1526.38.1.39","article-title":"Circulating nerve growth factor in primary and secondary Raynaud's syndrome \u2014 results of a pilot study","volume":"38","author":"Klein-Weigel","year":"2009","journal-title":"Vasa"},{"key":"10.1016\/j.autrev.2013.12.001_bb0525","first-page":"3","article-title":"The effect of cooling on in vitro vascular prostacyclin and platelet thromboxane A2 synthesis: relevance to cold-induced pathology","volume":"4","author":"Jeremy","year":"1988","journal-title":"Microcirc Endothelium Lymphatics"},{"key":"10.1016\/j.autrev.2013.12.001_bb0530","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/art.11060","article-title":"Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease","volume":"48","author":"Rajagopalan","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0535","first-page":"221","article-title":"The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases","volume":"25","author":"Rychlik-Golema","year":"2006","journal-title":"Int Angiol"},{"issue":"Suppl. 12","key":"10.1016\/j.autrev.2013.12.001_bb0540","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199204002-00002","article-title":"Molecular cloning of human endothelin (ET) receptors ETA and ETB","volume":"20","author":"Haendler","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0545","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bcp.2012.03.020","article-title":"Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease","volume":"84","author":"Mazzuca","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0550","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0140-6736(90)92766-B","article-title":"Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon","volume":"336","author":"Zamora","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.12.001_bb0555","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/oem.53.2.118","article-title":"Serum endothelin concentrations in workers exposed to vibration","volume":"53","author":"Palmer","year":"1996","journal-title":"Occup Environ Med"},{"key":"10.1016\/j.autrev.2013.12.001_bb0560","first-page":"1268","article-title":"Localization of endothelin-1 and its binding sites in scleroderma skin","volume":"21","author":"Vancheeswaran","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0565","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3899\/jrheum.081030","article-title":"Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis","volume":"36","author":"Sulli","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0570","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10067-009-1288-7","article-title":"Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis","volume":"29","author":"Kim","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0575","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3181\/00379727-221-44414","article-title":"Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling","volume":"221","author":"Kirchengast","year":"1999","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.autrev.2013.12.001_bb0580","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/01.hjh.0000226182.60321.69","article-title":"Role of the renin\u2013angiotensin\u2013aldosterone system in vascular remodeling and inflammation: a clinical review","volume":"24","author":"Duprez","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.autrev.2013.12.001_bb0585","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.11364","article-title":"Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors","volume":"50","author":"Kawaguchi","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0590","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/art.20214","article-title":"Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease","volume":"50","author":"Furspan","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0595","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.autrev.2009.08.004","article-title":"Homocysteine and Raynaud's phenomenon: a review","volume":"9","author":"Lazzerini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0600","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1756-185X.2011.01597.x","article-title":"Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus","volume":"14","author":"Buyukhatipoglu","year":"2011","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0605","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.12.001_bb0610","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1","article-title":"Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis","volume":"42","author":"Rajkumar","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0615","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10456-013-9338-9","article-title":"Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine","volume":"16","author":"Cipriani","year":"2013","journal-title":"Angiogenesis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0620","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.4049\/jimmunol.174.9.5740","article-title":"Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis","volume":"174","author":"Laplante","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0625","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.autrev.2011.04.019","article-title":"Angiogenic cytokines and growth factors in systemic sclerosis","volume":"10","author":"Liakouli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0630","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3899\/jrheum.080924","article-title":"Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis","volume":"36","author":"Blaise","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0635","doi-asserted-by":"crossref","first-page":"280","DOI":"10.5271\/sjweh.2140","article-title":"Pathological changes observed in the finger biopsy of patients with vibration-induced white finger","volume":"12","author":"Takeuchi","year":"1986","journal-title":"Scand J Work Environ Health"},{"key":"10.1016\/j.autrev.2013.12.001_bb0640","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-642-29423-5_4","article-title":"Platelet interaction with the vessel wall","author":"de Groot","year":"2012","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0645","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/ard.55.2.122","article-title":"Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis","volume":"55","author":"Herrick","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0650","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/030097401753180372","article-title":"Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis","volume":"30","author":"Silveri","year":"2001","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0655","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3899\/jrheum.100780","article-title":"Plasma platelet-derived microparticles in patients with connective tissue diseases","volume":"38","author":"Oyabu","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0660","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1445-5994.2010.02399.x","article-title":"Platelet activation in patients with the Raynaud phenomenon","volume":"42","author":"Polidoro","year":"2012","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2013.12.001_bb0665","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3109\/09537104.2011.618563","article-title":"Increased mean platelet volume in primary Raynaud's phenomenon","volume":"23","author":"Shemirani","year":"2012","journal-title":"Platelets"},{"key":"10.1016\/j.autrev.2013.12.001_bb0670","first-page":"375","article-title":"Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon","volume":"11","author":"Marasini","year":"1992","journal-title":"Int J Microcirc Clin Exp"},{"key":"10.1016\/j.autrev.2013.12.001_bb0675","first-page":"4","article-title":"The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis","volume":"19","author":"Herrick","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0680","first-page":"1477","article-title":"Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis","volume":"21","author":"Herrick","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0685","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0008-6363(02)00728-9","article-title":"Current pathophysiological views on vibration-induced Raynaud's phenomenon","volume":"57","author":"Stoyneva","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2013.12.001_bb0690","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.1780380807","article-title":"Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis","volume":"38","author":"Bruckdorfer","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0695","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/40.4.401","article-title":"Antibodies against oxidized low-density lipoproteins in systemic sclerosis","volume":"40","author":"Herrick","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0700","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/1529-0131(200004)43:4<894::AID-ANR22>3.0.CO;2-4","article-title":"Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury","volume":"43","author":"Solans","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0705","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1177\/000331979704800908","article-title":"The hemorheologic effects of hand-transmitted vibration","volume":"48","author":"Greenstein","year":"1997","journal-title":"Angiology"},{"key":"10.1016\/j.autrev.2013.12.001_bb0710","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.51.2.249","article-title":"White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome","volume":"51","author":"Lau","year":"1992","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0715","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/art.21912","article-title":"Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance","volume":"54","author":"Hirschl","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0720","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2011.03.001","article-title":"Autoantibodies to intracellular antigens: generation and pathogenetic role","volume":"10","author":"Racanelli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0725","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0730","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0735","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clim.2010.06.008","article-title":"The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3)","volume":"137","author":"Perosa","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0740","doi-asserted-by":"crossref","first-page":"e61453","DOI":"10.1371\/journal.pone.0061453","article-title":"Autoantibodies recognizing the amino terminal 1\u201317 segment of CENP-A display unique specificities in systemic sclerosis","volume":"8","author":"Favoino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2013.12.001_bb0745","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kem241","article-title":"Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts","volume":"46","author":"Fineschi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0750","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1002\/1529-0131(200011)43:11<2550::AID-ANR24>3.0.CO;2-H","article-title":"Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95","volume":"43","author":"Sgonc","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0755","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0889-857X(03)00021-8","article-title":"The vasculopathy of Raynaud's phenomenon and scleroderma","volume":"29","author":"Flavahan","year":"2003","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2013.12.001_bb0760","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2008.096677","article-title":"EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)","volume":"68","author":"Kowal-Bielecka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0765","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.mvr.2011.04.004","article-title":"The effect of metoprolol alone and combined metoprolol\u2013felodipin on the digital microcirculation of patients with primary Raynaud's syndrome","volume":"82","author":"Csiki","year":"2011","journal-title":"Microvasc Res"},{"key":"10.1016\/j.autrev.2013.12.001_bb0770","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0775","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/41.3.324","article-title":"Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis","volume":"41","author":"Anderson","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0780","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0785","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1136\/annrheumdis-2012-201536","article-title":"A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon","volume":"72","author":"Hummers","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0790","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/art.22965","article-title":"Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril","volume":"56","author":"Gliddon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0795","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","article-title":"Effects of cilostazol in patients with Raynaud's syndrome","volume":"92","author":"Rajagopalan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0800","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.autrev.2013.12.001_bb0805","first-page":"499","article-title":"Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study","volume":"18","author":"Denton","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0810","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/rheumatology\/keh390","article-title":"Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis","volume":"44","author":"Thompson","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0815","first-page":"CD006687","article-title":"Oral vasodilators for primary Raynaud's phenomenon","author":"Vinjar","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0820","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3899\/jrheum.090270","article-title":"Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis","volume":"36","author":"Schiopu","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0825","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.30195","article-title":"Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis","volume":"63","author":"Herrick","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0830","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1529-0131(200108)44:8<1841::AID-ART322>3.0.CO;2-8","article-title":"Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis","volume":"44","author":"Thompson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0835","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2013.12.001_bb0840","first-page":"1830","article-title":"Low versus high-dose iloprost therapy over 21days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study","volume":"35","author":"Kawald","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0845","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kel038","article-title":"Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol","volume":"45","author":"Milio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0850","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0855","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2013.12.001_bb0860","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/ard.2010.130658","article-title":"Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial","volume":"70","author":"Matucci-Cerinic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2013.12.001_bb0865","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3899\/jrheum.100358","article-title":"Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension","volume":"37","author":"Rosato","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0870","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0875","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/acr.21622","article-title":"Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon","volume":"64","author":"Fava","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2013.12.001_bb0880","first-page":"1801","article-title":"Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers","volume":"35","author":"Abou-Raya","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0885","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10067-009-1251-7","article-title":"The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients","volume":"28","author":"Rosato","year":"2009","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2013.12.001_bb0890","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/rheumatology\/ket019","article-title":"Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study","volume":"52","author":"Parisi","year":"2013","journal-title":"Rheumatology (Oxford)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997214000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T18:31:56Z","timestamp":1688927516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997214000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":178,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1568997214000020"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.12.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Raynaud's phenomenon: From molecular pathogenesis to therapy","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}